March 25, 2022 11:16 AM EDTUpdated 02:56 PM
R&D
Coronavirus

Big Phar­ma has skirt­ed long Covid, but a pipeline of small biotechs is test­ing treat­ments for lin­ger­ing symp­toms

Kyle LaHucik

Senior Reporter

Long Covid has been part­ly mys­te­ri­ous, due to the nascen­cy of SARS-CoV-2 as well as the vast­ness of lin­ger­ing symp­toms ex­pe­ri­enced by mil­lions of peo­ple …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times